Under a flexible agreement, DynPort Vaccine Co. (DVC) of Frederick, Maryland has netted a contract worth up to $159 million with the National Institute of Allergy and Infectious Diseases (NIAID), an affiliate of Bethesda-based National Institutes of Health.
Classified as an indefinite-delivery, indefinite-quantity contract, the deal will enable DynPort to explore manufacturing and testing of potential products for up to a decade under the Institute’s auspices. DynPort is one of four firms to receive the contract.
"DVC has been successfully conducting product development for government agencies for nearly 20 years," DVC President Gary Nabors said. "Together with our teaming partners, we have the talent and experience base to conduct the wide array of medical product development activities needed by our customer.”
NIAID specializes in infectious, immunologic and allergic diseases. DynPort plans to develop production and testing methods; coordinate manufacturing with industry standards, known as current good manufacturing practices; and provide regulatory support as new treatments emerge for infectious diseases.
“NIAID has been at the forefront of implementing new therapies, vaccines, diagnostic tests and other technologies that have improved the lives of millions of people around the world and we are honored to support their efforts," Nabors said.
